BioVaxys Technology Corp.
BIOV
CNSX
01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 777.20K | 1.09M | 585.80K | 358.30K | 254.40K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 800.40K | 1.09M | 585.80K | 358.30K | 254.40K |
Operating Income | -800.40K | -1.09M | -585.80K | -358.30K | -254.40K |
Income Before Tax | -753.10K | -2.01M | -866.50K | -399.70K | 383.70K |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -753.10K | -2.01M | -866.50K | -399.70K | 383.70K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -753.10K | -2.01M | -866.50K | -399.70K | 383.70K |
EBIT | -800.40K | -1.09M | -585.80K | -358.30K | -254.40K |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EPS Diluted | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Basic Shares Outstanding | 262.24M | 242.56M | 220.08M | 208.25M | 145.27M |
Average Diluted Shares Outstanding | 262.24M | 242.56M | 220.08M | 208.25M | 145.27M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |